| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alin Abreu, Alejandro Pinzón Tovar, Rafael Castellanos, Alex Valenzuela, Claudia Milena Gómez Giraldo, Alejandro Castellanos Pinedo, Doly Pantoja Guerrero, Carlos Alfonso Builes Barrera, Humberto Ignacio Franco, Antônio Ribeiro-Oliveira, Lucio Vilar, Raquel S Jallad, Felipe Gaia Duarte, Mônica Gadelha, Cesar Luiz Boguszewski, Julio Abucham, Luciana A Naves, Nina Rosa C Musolino, Maria Estela Justamante de Faria, Ciliana Rossato, Marcello D Bronstei. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. vol 19. issue 4. 2017-03-22. PMID:27279011. |
acromegaly is a rare, insidious disease resulting from the overproduction of growth hormone (gh) and insulin-like growth factor 1 (igf-1), and is associated with a range of comorbidities. |
2017-03-22 |
2023-08-13 |
Not clear |
| F Zoicas, A Kleindienst, B Mayr, M Buchfelder, R Megele, C Schöf. Screening for Acromegaly in Patients with Carpal Tunnel Syndrome: A Prospective Study (ACROCARP). Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 48. issue 7. 2017-03-06. PMID:26849823. |
in 2 patients acromegaly was ruled out using random gh and ogtt. |
2017-03-06 |
2023-08-13 |
Not clear |
| Naoki Edo, Koji Morita, Hisanori Suzuki, Akira Takeshita, Megumi Miyakawa, Noriaki Fukuhara, Hiroshi Nishioka, Shozo Yamada, Yasuhiro Takeuch. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study. Endocrine journal. vol 63. issue 5. 2017-03-03. PMID:26949262. |
low insulin resistance after surgery predicts poor gh suppression one year after complete resection for acromegaly: a retrospective study. |
2017-03-03 |
2023-08-13 |
Not clear |
| Naoki Edo, Koji Morita, Hisanori Suzuki, Akira Takeshita, Megumi Miyakawa, Noriaki Fukuhara, Hiroshi Nishioka, Shozo Yamada, Yasuhiro Takeuch. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study. Endocrine journal. vol 63. issue 5. 2017-03-03. PMID:26949262. |
remission of acromegaly is defined as a nadir in gh <1.0 ng/ml during a 75-g oral glucose tolerance test (75gogtt) and insulin-like growth factor-1 (igf-1) normalization. |
2017-03-03 |
2023-08-13 |
Not clear |
| Naoki Edo, Koji Morita, Hisanori Suzuki, Akira Takeshita, Megumi Miyakawa, Noriaki Fukuhara, Hiroshi Nishioka, Shozo Yamada, Yasuhiro Takeuch. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study. Endocrine journal. vol 63. issue 5. 2017-03-03. PMID:26949262. |
we included 110 cases of acromegaly with complete adenoma resection, no preoperative treatment, preoperative glycosylated hemoglobin <6.5%, preoperative basal plasma glucose <126 mg/dl, gh nadir <1.0 ng/ml during a 75gogtt, and normalized igf-1 at the first postoperative year evaluation, whereupon patients were divided into two groups: control (gh nadir <0.4 ng/ml) and high gh (gh nadir >0.4 ng/ml). |
2017-03-03 |
2023-08-13 |
Not clear |
| Filippo Maffezzoni, Anna Maria Formenti, Gherardo Mazziotti, Stefano Frara, Andrea Giustin. Current and future medical treatments for patients with acromegaly. Expert opinion on pharmacotherapy. vol 17. issue 12. 2017-02-22. PMID:27352098. |
acromegaly is a relatively rare condition of growth hormone (gh) excess associated with significant morbidity and, when left untreated, high mortality. |
2017-02-22 |
2023-08-13 |
Not clear |
| Filippo Maffezzoni, Anna Maria Formenti, Gherardo Mazziotti, Stefano Frara, Andrea Giustin. Current and future medical treatments for patients with acromegaly. Expert opinion on pharmacotherapy. vol 17. issue 12. 2017-02-22. PMID:27352098. |
therapy for acromegaly is targeted at decreasing gh and insulin-like growth hormone 1 levels, ameliorating patients' symptoms and decreasing any local compressive effects of the pituitary adenoma. |
2017-02-22 |
2023-08-13 |
Not clear |
| Filippo Maffezzoni, Anna Maria Formenti, Gherardo Mazziotti, Stefano Frara, Andrea Giustin. Current and future medical treatments for patients with acromegaly. Expert opinion on pharmacotherapy. vol 17. issue 12. 2017-02-22. PMID:27352098. |
the therapeutic options for acromegaly include surgery, medical therapies (such as dopamine agonists, somatostatin receptor ligands and the gh receptor antagonist pegvisomant) and radiotherapy. |
2017-02-22 |
2023-08-13 |
Not clear |
| Laura Chinezu, Alexandre Vasiljevic, Jacqueline Trouillas, Marion Lapoirie, Emmanuel Jouanneau, Gérald Ravero. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. European journal of endocrinology. vol 176. issue 2. 2017-02-07. PMID:27913611. |
silent somatotroph tumours are growth hormone (gh) immunoreactive (ir) pituitary tumours without clinical and biological signs of acromegaly. |
2017-02-07 |
2023-08-13 |
Not clear |
| F Malgo, N A T Hamdy, T J Rabelink, H M Kroon, K M J A Claessen, A M Pereira, N R Biermasz, N M Appelman-Dijkstr. Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. European journal of endocrinology. vol 176. issue 3. 2017-02-03. PMID:28077497. |
acromegaly is a rare disease caused by excess growth hormone (gh) production by the pituitary adenoma. |
2017-02-03 |
2023-08-13 |
Not clear |
| Vera Chesnokova, Svetlana Zonis, Cuiqi Zhou, Maria Victoria Recouvreux, Anat Ben-Shlomo, Takako Araki, Robert Barrett, Michael Workman, Kolja Wawrowsky, Vladimir A Ljubimov, Magdalena Uhart, Shlomo Melme. Growth hormone is permissive for neoplastic colon growth. Proceedings of the National Academy of Sciences of the United States of America. vol 113. issue 23. 2017-01-27. PMID:27226307. |
growth hormone (gh) excess in acromegaly is associated with increased precancerous colon polyps and soft tissue adenomas, whereas short-stature humans harboring an inactivating gh receptor mutation do not develop cancer. |
2017-01-27 |
2023-08-13 |
mouse |
| Vera Chesnokova, Svetlana Zonis, Cuiqi Zhou, Maria Victoria Recouvreux, Anat Ben-Shlomo, Takako Araki, Robert Barrett, Michael Workman, Kolja Wawrowsky, Vladimir A Ljubimov, Magdalena Uhart, Shlomo Melme. Growth hormone is permissive for neoplastic colon growth. Proceedings of the National Academy of Sciences of the United States of America. vol 113. issue 23. 2017-01-27. PMID:27226307. |
administration of a gh receptor (ghr) blocker in acromegaly patients induced colon p53 and adenomatous polyposis coli (apc), reversing progrowth gh signals. |
2017-01-27 |
2023-08-13 |
mouse |
| Kevin C J Yuen, Anthony P Heaney, Vera Popovi. Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician. Endocrine. vol 52. issue 2. 2017-01-26. PMID:26732039. |
evidence supporting this notion is derived from animal model studies, epidemiological studies, experience from patients with acromegaly, molecular therapeutic manipulation of gh and igf-i actions, and individuals with gh receptor and congenital igf-i deficiencies. |
2017-01-26 |
2023-08-13 |
Not clear |
| Yasuyuki Kinoshita, Atsushi Tominaga, Satoshi Usui, Kazunori Arita, Tetsuhiko Sakoguchi, Kazuhiko Sugiyama, Kaoru Kuris. Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy. Neurosurgical review. vol 39. issue 2. 2017-01-24. PMID:26785642. |
clinical features and natural course of acromegaly in patients with discordance in the nadir gh level on the oral glucose test and the igf-1 value at 3 months after adenomectomy. |
2017-01-24 |
2023-08-13 |
human |
| Yasuyuki Kinoshita, Atsushi Tominaga, Satoshi Usui, Kazunori Arita, Tetsuhiko Sakoguchi, Kazuhiko Sugiyama, Kaoru Kuris. Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy. Neurosurgical review. vol 39. issue 2. 2017-01-24. PMID:26785642. |
the aim of this study was to evaluate the clinical features and natural course of postoperative acromegaly associated with discordant gh and igf-1 levels over a postoperative period. |
2017-01-24 |
2023-08-13 |
human |
| Yasuyuki Kinoshita, Atsushi Tominaga, Satoshi Usui, Kazunori Arita, Tetsuhiko Sakoguchi, Kazuhiko Sugiyama, Kaoru Kuris. Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy. Neurosurgical review. vol 39. issue 2. 2017-01-24. PMID:26785642. |
on the other hand, four patients in the high-gh group exhibited an elevated nadir gh level higher than 1.0 μg/l on repeated ogtts after 3 months, and one patient experienced a recurrence of acromegaly. |
2017-01-24 |
2023-08-13 |
human |
| S Pekic, M Stojanovic, V Popovi. Contemporary issues in the evaluation and management of pituitary adenomas. Minerva endocrinologica. vol 40. issue 4. 2017-01-19. PMID:25900682. |
they may be clinically silent or secrete anterior pituitary hormones in excess such as prolactin, growth hormone (gh), or adrenocorticotropic hormone (acth) causing diseases like prolactinoma, acromegaly, cushing's disease or rarely thyroid-stimulating hormone (tsh) or gonadotropins (lh, fsh). |
2017-01-19 |
2023-08-13 |
Not clear |
| J J Zhang, D Nellesen, W H Ludlam, M P Near. Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder. Journal of medical economics. vol 19. issue 4. 2017-01-17. PMID:26629745. |
acromegaly is a rare disorder characterized by the over-production of growth hormone (gh). |
2017-01-17 |
2023-08-13 |
Not clear |
| Virgilio Melgar, Etual Espinosa, Dalia Cuenca, Vanessa Valle, Moisés Mercad. [Current diagnosis and treatment of acromegaly]. Revista medica del Instituto Mexicano del Seguro Social. vol 53. issue 1. 2017-01-10. PMID:25680646. |
acromegaly is a rare condition characterized by the excessive secretion of growth hormone (gh), usually by a pituitary adenoma. |
2017-01-10 |
2023-08-13 |
Not clear |
| Virgilio Melgar, Etual Espinosa, Dalia Cuenca, Vanessa Valle, Moisés Mercad. [Current diagnosis and treatment of acromegaly]. Revista medica del Instituto Mexicano del Seguro Social. vol 53. issue 1. 2017-01-10. PMID:25680646. |
the biochemical diagnosis of acromegaly rests on the demonstration of an autonomous secretion of gh by means of the measurement of glucose-suppressed gh levels and the serum concentration of insulin like growth factor type 1 (igf-1). |
2017-01-10 |
2023-08-13 |
Not clear |